Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical TechnologiesNMTC -2.02%21 EV-to-FCF is -1.86 as of Sep. 09, 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 410 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 243902.2% on this metric.
The historical rank and industry rank for NeuroOne Medical Technologies's EV-to-FCF or its related term are showing as below:
NMTC'
s EV-to-FCF Range Over the Past 10 Years
Min: -18.34 Med: -2.36 Max: 0.39
Current: -1.86
During the past 13 years, the highest EV-to-FCF of NeuroOne Medical Technologies was 0.39. The lowest was -18.34. And the median was -2.36.
NMTC's EV-to-FCF is ranked worse than 100% of 410
companies
in the Medical Devices & Instruments industry
Industry Median: 23.64
vs NMTC: -1.86
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeuroOne Medical Technologies (NAS:NMTC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeuroOne Medical Technologies's PE Ratio (TTM) for today is calculated as:
NeuroOne Medical Technologies's share price for today is $1.6706.
NeuroOne Medical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NeuroOne Medical Technologies EV-to-FCF Related Terms
NeuroOne Medical Technologies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's EV-to-FCF falls into.
NeuroOne Medical Technologies's current Enterprise Value is $13.34 Mil.
NeuroOne Medical Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a EV-to-FCF of -1.86 as of Sep. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NeuroOne Medical Technologies and its competitors. According to the industry distribution chart, NeuroOne Medical Technologies ranks #999999 out of 410 companies in the Medical Devices & Instruments industry.
Is NeuroOne Medical Technologies' EV-to-FCF too high?
NeuroOne Medical Technologies' current EV-to-FCF is -1.86. Based on the distribution chart, NeuroOne Medical Technologies ranks #999999 out of 410 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' EV-to-FCF compare to PMI and HSCS?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #999999 out of 410 companies for EV-to-FCF. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median EV-to-FCF is 23.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current EV-to-FCF is -1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current EV-to-FCF of -1.86. The current EV-to-FCF is -1.86. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current EV-to-FCF is -1.86 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
